ShockWave Medical, Inc. Logo

ShockWave Medical, Inc.

SWAV

(2.5)
Stock Price

334,75 USD

10.81% ROA

24.79% ROE

76.34x PER

Market Cap.

12.567.686.625,00 USD

103.33% DER

0% Yield

20.75% NPM

ShockWave Medical, Inc. Stock Analysis

ShockWave Medical, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ShockWave Medical, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (47.48%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (10%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

6 PBV

The stock's high Price-to-Book Value (P/BV) ratio (10.23x) suggests it's overvalued, potentially making it an expensive investment.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-2.335) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

ShockWave Medical, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ShockWave Medical, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

ShockWave Medical, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ShockWave Medical, Inc. Revenue
Year Revenue Growth
2017 1.719.000
2018 12.263.000 85.98%
2019 42.927.000 71.43%
2020 67.789.000 36.68%
2021 237.146.000 71.41%
2022 489.733.000 51.58%
2023 744.080.000 34.18%
2023 730.230.000 -1.9%
2024 875.220.000 16.57%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ShockWave Medical, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2017 17.963.000
2018 22.698.000 20.86%
2019 32.853.000 30.91%
2020 36.926.000 11.03%
2021 50.544.000 26.94%
2022 81.679.000 38.12%
2023 158.104.000 48.34%
2023 145.647.000 -8.55%
2024 177.864.000 18.11%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ShockWave Medical, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 5.422.000
2018 5.979.000 9.32%
2019 14.134.000 57.7%
2020 23.863.000 40.77%
2021 34.747.000 31.32%
2022 56.929.000 38.96%
2023 85.804.000 33.65%
2023 95.265.000 9.93%
2024 116.932.000 18.53%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ShockWave Medical, Inc. EBITDA
Year EBITDA Growth
2017 -30.031.000
2018 -39.911.000 24.76%
2019 -49.494.000 19.36%
2020 -64.407.000 23.15%
2021 -7.739.000 -732.24%
2022 122.714.000 106.31%
2023 190.356.000 35.53%
2023 176.351.000 -7.94%
2024 224.204.000 21.34%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ShockWave Medical, Inc. Gross Profit
Year Gross Profit Growth
2017 -1.117.000
2018 5.013.000 122.28%
2019 25.768.000 80.55%
2020 46.798.000 44.94%
2021 195.708.000 76.09%
2022 424.737.000 53.92%
2023 646.028.000 34.25%
2023 634.842.000 -1.76%
2024 762.392.000 16.73%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ShockWave Medical, Inc. Net Profit
Year Net Profit Growth
2017 -30.615.000
2018 -41.102.000 25.51%
2019 -51.109.000 19.58%
2020 -65.699.000 22.21%
2021 -9.136.000 -619.12%
2022 215.996.000 104.23%
2023 139.944.000 -54.34%
2023 147.278.000 4.98%
2024 221.384.000 33.47%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ShockWave Medical, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 -2
2018 -2 0%
2019 -2 50%
2020 -2 -100%
2021 0 0%
2022 6 100%
2023 4 -100%
2023 4 25%
2024 6 20%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ShockWave Medical, Inc. Free Cashflow
Year Free Cashflow Growth
2017 -30.772.000
2018 -43.446.000 29.17%
2019 -51.924.000 16.33%
2020 -82.704.000 37.22%
2021 2.597.000 3284.6%
2022 92.606.000 97.2%
2023 165.458.000 44.03%
2023 44.113.000 -275.08%
2024 27.451.000 -60.7%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ShockWave Medical, Inc. Operating Cashflow
Year Operating Cashflow Growth
2017 -30.347.000
2018 -41.465.000 26.81%
2019 -48.107.000 13.81%
2020 -71.184.000 32.42%
2021 15.036.000 573.42%
2022 117.732.000 87.23%
2023 196.053.000 39.95%
2023 50.651.000 -287.07%
2024 35.840.000 -41.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ShockWave Medical, Inc. Capital Expenditure
Year Capital Expenditure Growth
2017 425.000
2018 1.981.000 78.55%
2019 3.817.000 48.1%
2020 11.520.000 66.87%
2021 12.439.000 7.39%
2022 25.126.000 50.49%
2023 30.595.000 17.88%
2023 6.538.000 -367.96%
2024 8.389.000 22.06%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ShockWave Medical, Inc. Equity
Year Equity Growth
2017 -83.292.000
2018 30.531.000 372.81%
2019 192.653.000 84.15%
2020 225.654.000 14.62%
2021 241.830.000 6.69%
2022 511.316.000 52.7%
2023 668.677.000 23.53%
2023 601.245.000 -11.22%
2024 751.757.000 20.02%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ShockWave Medical, Inc. Assets
Year Assets Growth
2017 59.304.000
2018 53.421.000 -11.01%
2019 231.938.000 76.97%
2020 272.042.000 14.74%
2021 345.682.000 21.3%
2022 646.089.000 46.5%
2023 1.566.563.000 58.76%
2023 1.473.959.000 -6.28%
2024 1.643.747.000 10.33%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ShockWave Medical, Inc. Liabilities
Year Liabilities Growth
2017 142.596.000
2018 22.890.000 -522.96%
2019 39.285.000 41.73%
2020 46.388.000 15.31%
2021 103.852.000 55.33%
2022 134.773.000 22.94%
2023 897.886.000 84.99%
2023 872.714.000 -2.88%
2024 891.990.000 2.16%

ShockWave Medical, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
21.13
Net Income per Share
4.39
Price to Earning Ratio
76.34x
Price To Sales Ratio
15.95x
POCF Ratio
63.06
PFCF Ratio
75.65
Price to Book Ratio
16.6
EV to Sales
16.58
EV Over EBITDA
70.57
EV to Operating CashFlow
66
EV to FreeCashFlow
78.63
Earnings Yield
0.01
FreeCashFlow Yield
0.01
Market Cap
12,57 Bil.
Enterprise Value
13,06 Bil.
Graham Number
44.6
Graham NetNet
7.68

Income Statement Metrics

Net Income per Share
4.39
Income Quality
1.21
ROE
0.25
Return On Assets
0.1
Return On Capital Employed
0.11
Net Income per EBT
0.89
EBT Per Ebit
1.13
Ebit per Revenue
0.21
Effective Tax Rate
0.11

Margins

Sales, General, & Administrative to Revenue
0.13
Research & Developement to Revenue
0.21
Stock Based Compensation to Revenue
0.1
Gross Profit Margin
0.87
Operating Profit Margin
0.21
Pretax Profit Margin
0.23
Net Profit Margin
0.21

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
5.31
Free CashFlow per Share
4.46
Capex to Operating CashFlow
-0.16
Capex to Revenue
-0.04
Capex to Depreciation
-2.7
Return on Invested Capital
0.09
Return on Tangible Assets
0.11
Days Sales Outstanding
57.64
Days Payables Outstanding
35.04
Days of Inventory on Hand
395.92
Receivables Turnover
6.33
Payables Turnover
10.42
Inventory Turnover
0.92
Capex per Share
-0.85

Balance Sheet

Cash per Share
27,60
Book Value per Share
20,16
Tangible Book Value per Share
16.63
Shareholders Equity per Share
20.16
Interest Debt per Share
21.08
Debt to Equity
1.03
Debt to Assets
0.47
Net Debt to EBITDA
2.67
Current Ratio
13.81
Tangible Asset Value
0,62 Bil.
Net Current Asset Value
0,38 Bil.
Invested Capital
1.03
Working Capital
1,18 Bil.
Intangibles to Total Assets
0.08
Average Receivables
0,12 Bil.
Average Payables
0,01 Bil.
Average Inventory
109401000
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ShockWave Medical, Inc. Dividends
Year Dividends Growth

ShockWave Medical, Inc. Profile

About ShockWave Medical, Inc.

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

CEO
Mr. Douglas E. Godshall M.B.A.
Employee
1.468
Address
5403 Betsy Ross Drive
Santa Clara, 95054

ShockWave Medical, Inc. Executives & BODs

ShockWave Medical, Inc. Executives & BODs
# Name Age
1 Ms. Trinh Phung
Chief Accounting Officer, Principal Accounting Officer & Vice President of Finance
70
2 Ms. Debbie Kaster
Vice President of Investor Relations
70
3 Mr. Robert Fletcher
Senior Vice President of Marketing & Market Access
70
4 Mr. John M. Adams
Co-Founder and Technical Advisor
70
5 Mr. Isaac Zacharias
President & Chief Commercial Officer
70
6 Mr. Daniel Hawkins
Founder and Senior Advisor
70
7 Ms. Renee M. Gaeta
Chief Financial Officer
70
8 Mr. Douglas E. Godshall M.B.A.
President, Chief Executive Officer & Director
70
9 Mr. Hajime Tada J.D.
General Counsel & Secretary
70
10 Mr. Luis Morales
Senior Vice President of Global Operations
70

ShockWave Medical, Inc. Competitors